GCP
GANX icon

GSA Capital Partners’s Gain Therapeutics GANX Stock Holding History

GSA Capital Partners’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$606K Buy
312,467
+291,995
+1,426% +$635K 0.04% 796
2025
Q4 		$66K Buy
+20,472
New +$54.6K 0.01% 1559
2025
Q3 		– Sell
-12,756
Closed -$23K – 1800
2025
Q2 		$23K Buy
+12,756
New +$23.6K ﹤0.01% 1686

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GSA Capital Partners's GANX Position: Q1 2026 in Review

GSA Capital Partners increased its Gain Therapeutics (GANX) stake by 1,426% in Q1 2026, buying an estimated $635K and bringing the position to 312,467 shares worth $606K. The position accounts for 0.04% of the portfolio, ranked #796.

GSA Capital Partners first reported a position in GANX in Q2 2025 and has held it in 3 quarters since. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

  • GSA Capital Partners held 312,467 shares of Gain Therapeutics worth $606K as of Q1 2026.
  • GSA Capital Partners bought 291,995 Gain Therapeutics shares in Q1 2026, an estimated $635K.
  • Gain Therapeutics made up 0.04% of GSA Capital Partners's portfolio in Q1 2026, its #796 holding.
  • GSA Capital Partners first reported a position in Gain Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.